Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous levocarnitine for aluminum phosphide poisoning
IRCT20210720051946N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of levocarnitine in Aluminium phosphide poisoning (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: 24-hour mortality. Started Jun 2020; status: completed.
02
Drugs
levocarnitine
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on IRCT20210720051946N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210720051946N1.